ArticleClinical rheumatology2026
The value of arthroscopic synovectomy in the treatment of rheumatoid arthritis: A prospective cohort study.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe aim of this study is to investigate the effect of arthroscopic synovectomy (AS) on disease status in patients with rheumatoid arthritis (RA).
methodsA prospective study was conducted among patients with RA who underwent AS of the elbow or knee joints due to persistent swelling following conventional treatment, as well as control individuals who only received conventional treatment. All patients were evaluated at baseline and 4, 12, 24, 48, 96 weeks after AS. The coprimary outcomes were week 96 disease activity score (DAS)-28 remission and American College of Rheumatology improvement criteria (ACR20/50/70) remission. Key secondary outcomes were changes from baseline to week 96 in Mayo score, Lysoholm score, Health Assessment questionnaire (HAQ), patient's visual analogue scale, Magnetic Resonance Imaging in AS group. The correlation between synovial tissue biology and clinical response was analyzed.
resultsA total of 51 patients were included, with 17 accepted AS and conventional treatment, 34 only accepted conventional treatment. At week 96, more patients in AS group achieved DAS-28 remission [52.9% (9/17) vs 11.8% (4/34), P = 0.005] and ACR70 response [35.3% (6/11) vs 5.9% (2/34), P = 0.021] compared with control group. In AS group, DAS28 score [3.9 (3.7, 4.4) vs 2.8 (2.2, 3.4), P = 0.0002], MAYO score [52.5, (45.3, 62.8) vs 72 (60. 76.3), P = 0.021], Lysoholm score [55.5 (50, 59.5) vs 67.5 (63, 78), P = 0.020] and HAQ [4 (1, 6) vs 1 (0, 2), P = 0.034] improved significantly at week 4, 4, 12 and 48 respectively, and persisted until week 96. An increase in disease activity after AS was exclusively noted in the diffuse myeloid group.
conclusionThe disease activity and joint function of RA patients who underwent AS showed considerable improvement after surgery, which suggests that AS may enhance the likelihood of achieving remission in patients who had been treated with multiple DMARDs but have not achieved remission. Key Points • The rate of patients achieved disease remission in AS group at week 96 endpoint was better than that of the conventional treatment group. • Patients with RA after AS showed sustained improvement in disease activity and joint function, which remained stable for 96 weeks. • Only patients with diffuse myeloid synovial pathology exhibit increased disease activity.
Indexed as
Identifiers
42366265What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.